Titre :

Disease-Adaptive Drug Delivery to the Inflamed Intestinal Mucosa Using Poly(Lactic-<i>Co</i>-Glycolic Acid)-cyclodextrin Hybrid Nanocarriers

Auteur(s) :

Schreiner, J. [Auteur]
Goethe University Frankfurt
Brettner, F. E. B. [Auteur]
Goethe University Frankfurt
Steigert, S. [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Haessler, A. [Auteur]
Goethe University Frankfurt
Mols, R. [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Gier, S. [Auteur]
Goethe University Frankfurt
Jung, N. T. L. [Auteur]
Goethe University Frankfurt
Vogel-Kindgen, S. [Auteur]
Goethe University Frankfurt
Florin Muschert, Susanne [Auteur]
Advanced Drug Delivery Systems (ADDS) - U1008
Augustijns, P. [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Windbergs, M. [Auteur]
Goethe University Frankfurt

Titre de la revue :

Advanced Therapeutics

Nom court de la revue :

Adv. Therap.

Numéro :

8

Pagination :

2400368

Éditeur :

Wiley

Date de publication :

2025-01-19

ISSN :

2366-3987

Mot(s)-clé(s) en anglais :

amphiphilic cyclodextrins
biomolecular intestinal corona
disease-adaptive release
inflammation control
nanoparticles
pH-dependent release

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Fluctuating severity of symptoms is a common hallmark of many inflammatory disorders, including inflammatory bowel disease (IBD). Addressing the pH changes during active and resting phases in IBD-affected tissue, a ...
Lire la suite >Fluctuating severity of symptoms is a common hallmark of many inflammatory disorders, including inflammatory bowel disease (IBD). Addressing the pH changes during active and resting phases in IBD-affected tissue, a disease-adaptive nanocarrier system is designed for oral administration, enabling pH-dependent local drug release. The hybrid carrier combines poly(lactic-co-glycolic acid) and an amphiphilic cyclodextrin derivative, with physicochemical properties and drug release kinetics controlled by adjusting polymer ratios. The systems exhibited baseline drug release at pH 5 with increased rates at pH 2, which is characteristic of actively inflamed IBD tissue. Assessing the impact of biomolecule adhesion, biocorona formation was studied using ex vivo human intestinal fluids. Corona composition highly depended on the patient's prandial state and the nanocarrier matrix, with proteins predominating in the fasted state and lipids in the fed state. Notably, differences in the attachment of proteins and free fatty acids are detected in the latter. Transport studies using human in vitro models of the inflamed intestine revealed mucosal accumulation, facilitating localized drug delivery and effectively reducing cytokine levels to basal concentrations. This hybrid system highlights the potential of disease-adaptive drug release for inflammatory disease treatment and underscores the impact of biocorona formation on therapeutic performance in the gastrointestinal tract.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Advanced Drug Delivery Systems (ADDS) - U1008

Date de dépôt :

2025-02-27T22:00:42Z
2025-03-03T09:58:08Z